Clinical trial
Avelumab in G3 NEC
NCT03278405 · Sunnybrook Health Sciences Centre, Other · Completed
Key facts
| NCT number | NCT03278405 |
|---|---|
| Title | Avelumab in G3 NEC |
| Official title | A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas |
| Acronym | NET-001 |
| Lead sponsor | Sunnybrook Health Sciences Centre, Other |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Carcinoma |
| Intervention type | Drug |
| Interventions | Avelumab |
| Enrollment | 10 |
| Start date | Nov 15, 2017 |
| Primary completion | Aug 9, 2019 |
| Completion | Mar 12, 2020 |
| First posted | Sep 11, 2017 |
| Last update posted | Mar 18, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: